ANG Lifesciences India Reports Mixed Financial Results for Q2 FY25

ANG Lifesciences India, a microcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company’s stock has been given a ‘Strong Sell’ call by MarketsMOJO.

According to the financial report, ANG Lifesciences has seen a negative performance in the second quarter of the fiscal year 2024-2025. However, there has been an improvement in the company’s score from -33 to -16 in the last three months.

The company’s operating profit to interest ratio for the quarter was the highest in the last five quarters, indicating an improvement in its ability to manage interest payments. The profit before tax less other income was also the highest in the last five quarters, showing a positive trend in the near term.

On the other hand, the net sales and profit after tax for the half-yearly period have shown a decline of -42.83% year on year, indicating a negative trend in the company’s sales and profitability. The inventory turnover ratio and debtors turnover ratio have also decreased in the last five half-yearly periods, indicating a slower pace of selling inventory and settling debts.

The company’s operating cash flow for the last three years has been the lowest at Rs -9.49 crore, indicating a decline in cash revenues from business operations. The cash and cash equivalents for the half-yearly period have also decreased, indicating a deteriorating short-term liquidity situation. Additionally, the debt-equity ratio for the last five half-yearly periods has been the highest, indicating that the company is borrowing more to fund its operations, which may lead to a stressed liquidity situation.

Overall, ANG Lifesciences India’s financial performance for the quarter ending September 2024 has been negative, with some areas showing improvement while others showing a decline. Investors should carefully consider these factors before making any investment decisions.